human allogenic adipose-derived mesenchymal precursor cell therapy (Cellular Biomedicine Group)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Namehuman allogenic adipose-derived mesenchymal precursor cell therapy (Cellular Biomedicine Group)
Drug Alias Namehuman allogenic adipose-derived mesenchymal progenitor cell therapy (Cellular Biomedicine Group)allogenic haMPC (CBMG)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Stem cell therapy > Adipose stem cell therapy
Mechanisms of ActionStem cells stimulants
TargetsNot applicable
Therapy Area/IndicationsPulmonary Disease, Chronic ObstructiveAsthmaLiver Cirrhosis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesAbelZeta Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbelZeta Inc
Active IndicationsN/A
Inactive IndicationsPulmonary Disease, Chronic ObstructiveAsthmaLiver Cirrhosis +[4] 

Other Information

ATC CodeN/A
Related LinksN/A